The U.S. Food and Drug Administration (FDA) declined to approve Northera, CHTP’s blood pressure treatment, in 2012. CHTP resubmitted the drug in September. A research note from analysts at Wedbush indicated that an …
The 91.74% gain in Chelsea Therapeutics International Ltd (Nasdaq: CHTP) stock yesterday (Wednesday) is the latest biotech to see a massive one-day surge. More development-stage biotechs are nearing approval for new …
NASDAQ
Chelsea Therapeutics Presents Efficacy and Safety Data for NORTHERA at International Congress of Parkinson's Disease and Movement Disorders Chelsea Therapeutics Announces the Expiration of the Hart-Scott-Rodino …
[7:40AM]dieselEdge:$800ish on AFFY. This Trading System Works! Next Hot Stock Pick that we killed it on using the FOUS4 Trading System is none other than CHTP. I had been watching this stock for months. …
Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) shares are climbed 1.25% to $4.09 the U.S. Food and Drug Administration approves the company’s to start Phase II trial for its rheumatoid arthritis treatment. …
Central nervous system disorder specialist Chelsea Therapeutics International on Thursday said it had signed up to a bid from Denmark's H. Lundbeck that values its stock at up to $658 million. Chelsea CEO Joe Oliveto and …
Soaring
Chelsea Therapeutics International Ltd. ( CHTP) was a big mover last session, as the company saw its shares rise by almost 9% on the day. The move came on solid volume too with far more shares changing hands than …
After the announcement, CHTP stock price went down from $5 to $3.11. (NYSE:B) On Mar 28, 2012, FDA has issued a Complete Response Letter (CRL) regarding the new drug application (NDA) for Northera Capsules. …
Takeover
NEW YORK, June 28, 2016 /PRNewswire/ -- The following is being released by the law firm of Faruqi & Faruqi, …
Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) is definitely the soapiest soap opera of biopharma. It’s virtually impossible to keep track of the multiple trials, the changing endpoints mid-trial, the dubious and …